A biodistribution study shows where a therapy goes after dosing, how much reaches each tissue, and how long it persists. For AAV and other gene therapies it is a core part of the nonclinical package, and its design decisions, from species and route to tissue panel and assay sensitivity, are hard to change once animals are on study.
Regulatory Expectations
ICH S12 sets out nonclinical biodistribution considerations for gene therapy products, and FDA and EMA guidance on gene therapy nonclinical development expects data on distribution, persistence and shedding before first-in-human dosing. Regulators want to know which tissues receive vector, whether it is expressed there, how long it persists, whether it reaches the gonads, and whether it leaves the body.
Biodistribution is usually integrated into the GLP toxicology study, so that vector levels in each tissue can be read against any histopathology findings. A separate study is sometimes better when the tissue panel, time points or route differ from the toxicology design. Discuss the plan with the agency at a pre-IND or scientific advice meeting if the program is unusual.
Species and Route of Administration
Use a species in which the capsid transduces the target tissue in a way that resembles humans, and dose by the intended clinical route. Capsid tropism differs between species, so mouse data rarely substitute for a large-animal study when the clinical target is the CNS or another tissue where tropism varies. Nonhuman primates are common for CNS and systemic AAV programs, with rodents, pigs, dogs or sheep used where they suit the target organ or device.
For nonhuman primate AAV studies, screen animals for pre-existing neutralizing antibodies to the capsid before assignment. Pre-existing immunity can reduce transduction substantially, and seropositive animals are a common cause of variable or uninterpretable results.
Doses, Groups and Time Points
- Dose levels Include the intended clinical dose, scaled appropriately, and the highest dose in the toxicology study, so persistence and safety can be read across the range.
- Both sexes Include males and females unless the indication is sex-specific, and collect gonads from both.
- Time points Choose an early time point near peak vector levels, an intermediate one, and a late one that shows persistence or clearance. For AAV, which can persist for the life of the animal in non-dividing cells, the late time point often has to run for months.
- Group sizes Agree group sizes with the statistical and regulatory purpose in mind; nonhuman primate groups are small, so every animal and every tissue counts.
Tissue Panel
A typical panel covers the target tissues, the injection site, the liver, which takes up most systemically available AAV, the gonads, and other major organs such as heart, lung, kidney, spleen, lymph nodes, brain, spinal cord and dorsal root ganglia. Add tissues where the capsid is known to accumulate or where toxicology findings might appear. Shedding is sampled in blood, urine and feces, and sometimes saliva or nasal swabs.
Necropsy procedure matters as much as the assay. Collect tissues in a defined order from low to high expected vector levels, use dedicated or decontaminated instruments between tissues, and include procedural controls, because a few copies carried from liver to gonad can produce a false finding.
Analytical Methods
Vector genome copies are quantified by qPCR or ddPCR against a sequence unique to the vector and reported per microgram of genomic DNA. The assay should be qualified in every tissue matrix on the panel, with spike recovery to show the matrix does not suppress the signal. A sensitivity of 50 copies per microgram of genomic DNA or better has long been a common benchmark.
Vector DNA shows presence, not activity. Transgene mRNA by RT-qPCR or protein by immunohistochemistry, ELISA or mass spectrometry shows where the vector is expressed. Anti-capsid and anti-transgene antibody assays are often run on the same animals.
CNS Delivery Considerations
For intrathecal, ICV and intra-cisterna magna programs, delivery technique is a major source of variability. Dose volume relative to CSF volume, infusion rate, needle or catheter placement, and post-dose positioning all affect how vector spreads along the neuraxis, and some CSF-delivered vector still reaches the liver and other peripheral organs. Confirm delivery where possible, for example with imaging or a co-administered marker, and include dorsal root ganglia in both the biodistribution panel and the histopathology, since they are a recognized site of findings with CNS-delivered AAV.
Our team has hands-on surgical experience with intrathecal, ICV and cisterna magna delivery in large animals. Read more in our guides to CNS drug delivery methods and intrathecal catheterization.
Beyond AAV
The same questions apply to other modalities with different methods. Oligonucleotide programs measure tissue drug concentrations by hybridization ELISA or LC-MS/MS. Cell therapy programs track where administered cells migrate and persist, often with qPCR for human-specific DNA sequences in animal tissue or with in vivo imaging. Lentiviral and other integrating vectors add questions about integration that call for specialist assays.
Questions to Ask a Biodistribution CRO
- Assay qualification Has the qPCR or ddPCR assay been qualified in every tissue on our panel, and what sensitivity per microgram of DNA does it reach?
- Contamination control What necropsy procedures and controls prevent cross-contamination between tissues?
- Integration with toxicology Can biodistribution run within our toxicology study, and are bioanalysis and pathology in house?
- Animal screening Do you screen nonhuman primates for pre-existing neutralizing antibodies before assignment?
- Route experience How many studies have you run by our route and in our species, and how do you confirm the dose went where intended?
Our biodistribution CRO listings show which labs offer this work. Related lists include biologics CROs and CNS and neuroscience CROs.
Frequently Asked Questions
When is a biodistribution study needed for a gene therapy?
Regulators expect nonclinical biodistribution data before first-in-human dosing of most gene therapy products. ICH S12 describes the expectations, and FDA and EMA guidance on gene therapy nonclinical development asks for distribution, persistence and shedding data in a relevant species, usually by the intended clinical route. It is commonly integrated into the GLP toxicology study.
Can biodistribution be combined with the toxicology study?
Often, yes. Adding biodistribution cohorts or tissue collection to the GLP toxicology study links exposure in each tissue to any toxicology findings and saves animals, which matters most for nonhuman primates. A standalone study can make sense when the tissue panel, time points or route differ from the toxicology design.
How is AAV biodistribution measured?
Vector genome copies are quantified by qPCR or ddPCR and reported per microgram of genomic DNA, with the assay qualified in each tissue matrix. Transgene mRNA or protein shows where the vector is expressed. Shedding is measured in blood, urine, feces and sometimes saliva or nasal swabs.
Why does route of administration matter so much?
Route largely determines where vector goes. Intravenous AAV concentrates in the liver, while intrathecal, ICV and intra-cisterna magna dosing produce different patterns across the brain, spinal cord and dorsal root ganglia, and some CSF-delivered vector still reaches peripheral organs. Delivery technique and dose volume add variability, so biodistribution should be run by the clinical route with a well-practiced in-life team.